Skip to content

PTHS PTHS Net Income

Net Income at other companies

Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
-$3.29M-362%
Journey Medical Corporation logo
Journey Medical CorporationDERM
-$2.23M+45.2%
Opko Health logo
Opko HealthOPK
-$54.85M+18.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$37.89M+1,323%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$4.93M+63.7%
HRO
HarrowHROW
-$27.6M-55.2%

Segments

By segment

See full
Commercial operations-$10.29M
Research and Development operations$55K+103%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+92.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's net income?
PTHS (PTHS) reported net income of -$10.24M in Q1 2026.
How has PTHS's net income changed year-over-year?
PTHS's net income decreased by 420.2% year-over-year, from -$1.97M to -$10.24M.
What is the long-term trend for PTHS's net income?
Over 3 years (2022 to 2025), PTHS's net income has grown at a 160.2% compound annual growth rate (CAGR), from -$2.46M to -$43.32M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.